Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyungdong Pharm Co., Ltd. (011040:KRX), powered by AI.
Kyungdong Pharm Co., Ltd. is currently trading at ₩5,230. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kyungdong Pharm Co., Ltd. on Alpha Lenz.
Kyungdong Pharm Co., Ltd.'s P/E ratio is 18.9.
“Kyungdong Pharm Co., Ltd. trades at a P/E of 18.9 (fair value) with modest ROE of 3.8%.”
Ask for details →Kyungdong Pharm Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily engaged in the research, development, and distribution of various medicinal products. As a key player in the healthcare sector, Kyungdong Pharm focuses on creating high-quality prescription drugs, over-the-counter medications, and other health-related consumer goods, catering to a broad spectrum of therapeutic areas. The company enhances its market presence through a commitment to innovation and adherence to rigorous quality standards, ensuring the efficacy and safety of its pharmaceutical offerings. Founded in South Korea, it plays a vital role in meeting the healthcare needs both domestically and in international markets. Kyungdong Pharm is active in partnerships and collaborations with scientific institutions and hospitals that help advance its research capabilities and expand its global footprint. As part of the competitive pharmaceutical market, the company contributes significantly to advancements in medical treatments, positioning itself as a reliable source of healthcare solutions. Its strategic initiatives and robust product portfolio underline its importance in providing essential health care products to a diverse clientele.
“Kyungdong Pharm Co., Ltd. trades at a P/E of 18.9 (fair value) with modest ROE of 3.8%.”
Ask for details →Kyungdong Pharm Co., Ltd. (ticker: 011040) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $160.9B.
The current price is ₩5,230 with a P/E ratio of 18.87x and P/B of 0.7x.
ROE is 3.80% and operating margin is 3.91%. Annual revenue is $196.3B.